Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California Dana Farber Cancer Institute, Boston, Massachusetts Tennessee Oncology, Nashville, Tennessee Australia
Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit, Concord, New South Wales Macquarie University, Sydney, New South Wales Westmead Hospital, Westmead, New South Wales Peninsula & South Eastern Haematology and Oncology Group (PSEHOG), Frankston, Victoria Alfred Health, Melbourne, Victoria Linear Clinical Research, Nedlands, Western Australia New Zealand
Auckland City Hospital, Auckland Singapore
National Cancer Centre Singapore, Singapore Tan Tock Seng Hospital, Singapore